Skip to main content

Peer Review reports

From: EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

Original Submission
30 Sep 2018 Submitted Original manuscript
8 Feb 2019 Reviewed Reviewer Report - Ka-On Lam
25 Feb 2019 Reviewed Reviewer Report - Stephen Leong
28 Mar 2019 Author responded Author comments - Anna Dorothea Wagner
Resubmission - Version 2
28 Mar 2019 Submitted Manuscript version 2
25 Apr 2019 Author responded Author comments - Anna Dorothea Wagner
Resubmission - Version 3
25 Apr 2019 Submitted Manuscript version 3
Publishing
3 May 2019 Editorially accepted
24 May 2019 Article published 10.1186/s12885-019-5675-4

You can find further information about peer review here.

Back to article page